Explore Our Newsroom
03 April 2019
Learn about our Pacific Alliance initiative
Leading global law firm Baker McKenzie has advised Sofinnova Partners (Sofinnova) and New Enterprise Associates (NEA) in an oversubscribed CHF 22.5 million Series A financing round of Polyneuron Pharamceuticals AG (Polyneuron). The round was led by Sofinnova and co-led by NEA, with the participation of existing investors.
Swiss start-up Polyneuron is a spin-off of the University of Basel. It researches the advancement of drugs derived from a glycopolymer platform. Sofinnova and NEA have come on board to help Polyneuron take its lead product into a first-in-human clinical trial. The compound, PN-1007, is a potential treatment for anti-MAG neuropathy, a rare nervous system disease.
Baker McKenzie Zurich provided advice to Sofinnova and NEA with regard to all legal and tax aspects of the Series A Financing Round. The Baker McKenzie team comprised Martin Frey (Partner), Philippine Dalla Corte (Associate), Susanne Liebel-Kotz (Associate) and Christian Rioult (Associate).